Product Description
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies. (Sourced from: https://soseiheptares.com/news/783/129/Cancer-Research-UK-and-Sosei-Heptares-sign-agreement-to-advance-cancer-immunotherapy-candidate-into-clinical-trials.html)
Mechanisms of Action: EP4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cancer Research UK
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Prostate Cancer|Pancreatic Cancer|Esophageal Cancer|Head and Neck Cancer|Mesothelioma|Pheochromocytoma|Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05944237 |
CRUKD/22/001 | P2 |
Recruiting |
Pancreatic Cancer|Esophageal Cancer|Colorectal Cancer|Head and Neck Cancer|Mesothelioma|Sarcoma|Prostate Cancer|Pheochromocytoma |
2027-06-01 |
12% |
2025-06-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |